MENLO PARK, Calif.–(BUSINESS WIRE)–Octave, a leading digital health science company providing a new standard for the management of multiple sclerosis (MS) and other neurodegenerative diseases, today announced that its precision care solution for MS is now commercially available. Octave’s solution introduces quantitative and objective measures to help transform care of a domain guided by subjective and qualitative measures. With its multidimensional approach, the solution provides deeper insights into each patient’s underlying biology, radiographic status, and ongoing symptomatology. By creating and delivering new tools and services, Octave delivers actionable patient insights that can lead to better outcomes.
“We are excited to bring our precision care solution to the MS community, for which we have completed validation studies and continue to progress,” said William Hagstrom, Founder and CEO of Octave. “The solution addresses the challenges associated with disease at both the patient and population level, shifting from a subjective and reactive mode to a more quantitative and proactive world that facilitates informed and insightful care. We believe that better measurement leads to better management decisions that can have a profound impact on care delivery and outcomes.
Currently, the Octave solution is in use at several MS Centers of Excellence, including Michigan Institute for Neurological Disorders (MIND), Center for Neurology & Spine/MS Center of Arizona, USA Health, MS Center for Innovations in Care at Missouri Baptist Medical Center, North Central Neurology Associates and Hoag Pickup Family Neurosciences Institute. Additionally, the Rocky Mountain Multiple Sclerosis Clinic has partnered with Octave as a beta site.
“The level of innovation achieved by Octave and its research partners is unparalleled in the field of MS,” said Martin Belkin, DO, Physician and Medical Director of MIND’s MS Center. “The precision care solution provides those of us who have worked to treat this disease with more comprehensive and science-based tools and information than we have seen to date. We are now able to address many of the unmet needs these patients faced with more powerful and holistic information than ever before. »
Octave’s Precision Care solution provides a quantitative and objective measurement system designed to expand clinical knowledge of neurodegenerative diseases, starting with MS. It includes three dimensions to better understand the biology, radiographic status and symptomatology of a patient:
● The first and only MS-specific multivariate blood test which measures 18 biomarkers, revealing the underlying activated pathways and mechanisms that allow an accurate measurement of the patient’s disease activity.
● An MRI protocol specific to MS that combines human expertise with innovative imaging technology and delivers robust, intuitive, and clinically relevant information in a personalized report, tracking a patient over time.
● A multi-faceted program that provides ongoing patient care between office visits via an app, tracking their health and providing support to Octave’s MS Certified Nursing Partners.
All of this data is integrated and will be used to track patients through care pathways, develop decision support tools and populate dashboards for ease of use, also providing individual and population-level views for facilitate better stratification and contextual interventions.
“The tools currently available to assess patients with MS are subjective, qualitative and inadequate to address the complexities of managing a heterogeneous patient population in an ever-changing therapeutic landscape – something our early partners worked to overcome. for years,” said Maital Rasmussen, Chief Commercial Officer of Octave. “We are extremely proud to collaborate and partner with a network of leading centers across the United States to provide a comprehensive solution that better serves their patients and brings precision MS care.”
“Despite major advances in the treatment of MS over the past two decades, neurologists like myself need more sophisticated tools in the clinic to assess predictors of disease worsening,” said Barry Singer, MD. , director of the MS Center for Innovations at Missouri Baptist Medical Center. . “Octave’s state-of-the-art toolkit, including its panel of validated blood biomarkers and brain volume measurements, enables clinicians to improve the monitoring and care of their MS patients in a more comprehensive way than ‘previously.”
Octave has presented multiple validation datasets of solution components at major global neurology conferences, including ACTRIMS, CMSC, and ECTRIMS. In particular, the clinical results presented to date show that the MSDA multivariate blood test component is strongly associated with multiple disease activity endpoints and is significantly superior to the best performing univariate biomarker. Analytical studies demonstrate accurate, robust, and stable scores for expected sample processing and storage under real-world conditions. Additionally, studies have shown that the MSDA has the potential to serve as a quantitative tool to not only assess individual patients, but also to effectively monitor the overall level of disease activity within the entire population. of a clinic.
Additionally, the company presented data related to the imaging component of the solution which aims to create a single metric to quantify image quality differences to facilitate atrophy measurements, successfully creating a single metric to quantify differences in image quality over time.
With the launch of its solution, Octave is actively engaging in expanding partnerships with physicians and delivering its precision care capabilities to address challenges, issues and unmet needs across the healthcare ecosystem. MS, including pharmaceutical companies and health plans. The company is also committed to establishing collaborations and partnerships over time in a wide range of neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.
Octave was founded to provide a precision care solution for multiple sclerosis as well as a full range of neurodegenerative diseases. Its comprehensive information provides neurologists and their patients with objective measurements to facilitate informed care and shared decision-making for better patient outcomes.
Octave’s precision care solution is the first of its kind to accurately and objectively measure and help manage complex and costly neurodegenerative diseases, starting with multiple sclerosis. Octave has developed the first and only multivariate blood test to measure MS activity, enhanced MRI scans and protocols, and a digital clinical program with Octave’s MS care partners to ensure continuity of care .
Vendor: The solution provides neurologists with a longitudinal and holistic perspective of the patient along with comprehensive and actionable information, enabling more confident and informed care decisions.
Payer: The integrated and multidimensional approach allows payers to reduce the total cost of care by optimizing medications and healthcare utilization (hospitalizations, emergency room visits, MRIs, laboratories).
Pharmacy : Octave enables the pharmaceutical industry to optimize the entire drug discovery and development lifecycle as well as clinical trials and post-marketing with concrete evidence.
Through focused problem solving and innovative technologies, Octave’s platform generates, analyzes and combines data to create a new paradigm of MS care, leading to better patient outcomes.